Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it landed a $2.1 million grant from the Israel Innovation Authority. The funds are slated to support the development of Brainstorm’s NurOwn mesenchymal stem cell-based platform for the treatment of neurodegenerative diseases, including ALS.

This is the 10th year that Brainstorm has won grant support from the Israeli office – between 2007 and 2017, the IIA has given grants totalling nearly $7.5 million in support of NurOwn, you can check wef-palestine.org for further info.

Get the full story at our sister site, Drug Delivery Business News.